美国肝硬化相关住院中肝肾综合征的医疗负担与结局
基于美国全国住院患者样本库2016–2019年因酒精性肝病、慢性病毒性肝炎或NASH相关肝硬化合并急性肾损伤的住院资料,分析肝肾综合征的趋势、规模与结局。113,454例住院中16.5%发生肝肾综合征,2019年全国估计27,180例住院、经济负担42亿美元,住院死亡率18.9%且逐年下降但2019年肝肾综合征患者仍达23.7%。
要点
- 肝硬化合并急性肾损伤住院中16.5%为肝肾综合征,随时间趋势稳定。
- 倾向匹配后NASH较慢性病毒性肝炎的肝肾综合征 odds 高12%。
- 2019年全国估计27,180例肝肾综合征住院,经济负担42亿美元。
核心结论
- 肝肾综合征是16.5%肝硬化住院患者急性肾损伤的原因,带来显著医疗负担,2019年估计27,180例住院、需42亿美元住院费用。
- 住院死亡率随时间下降,但2019年肝肾综合征患者仍高达23.7%。
研究设计与样本
- 基于美国全国住院患者样本库(NIS)2016–2019年因酒精性肝病、慢性病毒性肝炎或NASH相关肝硬化合并急性肾损伤住院资料的分析。
- 共纳入113,454例住院,其中18,735例(16.5%)发生肝肾综合征。
- 采用1:1倾向匹配36,090例住院进行比较。
主要发现
- 肝肾综合征患者平均年龄56岁,女性36%,白人68%,酒精性肝病80%,NASH 7%,趋势稳定。
- 倾向匹配后NASH较慢性病毒性肝炎的肝肾综合征 odds 高12%。
- 2019年加权全国估计肝肾综合征住院27,180例(每10万美国人口8.3例),经济负担42亿美元。
- 平均住院日与总费用(酒精性肝病 vs 慢性病毒性肝炎 vs NASH)分别为11 vs 10.8 vs 9.2天和151,000 vs 157,000 vs 120,000美元,p < 0.001。
- 住院死亡率18.9%,肝肾综合征更高(25.8% vs 12%,p < 0.001),且每年下降15%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatorenal syndrome (HRS) contributes to significant morbidity and mortality in hospitalised patients with cirrhosis. AIMS: To examine recent trends, magnitude and outcomes of HRS in the National Inpatient Sample (NIS) database METHODS: Among the NIS database on cirrhosis hospitalisations (2016-2019) due to alcohol (ALD), chronic viral hepatitis (CVH), or NASH and complicated by acute kidney injury (AKI) were analyzed. RESULTS: Of 113,454 hospitalisations, 18,735 (16.5%) had HRS (mean age 56 years, 36% females, 68% whites, 80% ALD, 7% NASH) with a stable trend over time. Among 1:1 propensity-matched 36,090 hospitalisations, the odds of HRS were 12% higher in NASH versus CVH. Based on weighted national estimates, there were 27,180 (8.3 per 100,000 US population) HRS hospitalisations in 2019, with economic burden of $4.2 billion USD. Mean hospitalisation and total charges (ALD vs. CVH vs. NASH) were 11 versus 10.8 versus 9.2 days and 151,000 versus 157,000 versus 120,000 USD, respectively; p < 0.001. In-hospital mortality was 18.9%, higher in HRS (25.8 vs. 12%, p < 0.001), and decreased by 15% annually. Survivors were more likely to be discharged to short- or long-term care facilities (HRS vs. non-HRS [42 vs. 27%, p < 0.001]); only 28.7% received palliative care. CONCLUSION: HRS was the cause of AKI in 16.5% of patients hospitalised with cirrhosis and conferred significant healthcare burden with 27,180 HRS hospitalisations in 2019 and requiring an estimated 4.2 billion USD for hospital care. While there has been a decrease in in-hospital mortality over time, it remained high at 23.7% in 2019 in those with HRS.
引用
- Singal AK, Kuo YF, Reddy KR, et al. Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis-related hospitalisations in the US. Aliment Pharmacol Ther. 2022. PMID: 36196562. doi:10.1111/apt.17232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。